# DESCRIPTION

## TECHNOLOGY FIELD

- define technology field of lncRNA detection and cancer treatment

## BACKGROUND

- motivate need for lncRNA-based cancer therapy

## SUMMARY

- introduce CRISPRi screen for lncRNAs
- identify lncGRS-1 as glioma-specific therapeutic target
- describe human brain organoid model of malignant glioma
- outline method for identifying radiotherapy sensitizers
- describe methods for diagnosing and treating malignant glioma
- provide pharmaceutical composition and method for inhibiting glioma cell growth
- relate to human brain organoid model
- describe method of screening agent
- describe method of treating malignant glioma
- describe method of identifying radiotherapy sensitizer
- describe method of preparing sample
- describe system comprising nucleic acids

## DETAILED DESCRIPTION OF EMBODIMENTS

- provide general disclaimers

### Definitions

- define technical terms
- specify meaning of "comprising"
- define singular and plural forms
- define "about"
- define "nucleic acid" and "polynucleotide"
- define "biomarker"
- define "small non-coding RNA" and "long non-coding RNA"
- define "antisense activity" and "antisense compound"
- define "complementary" and "hybridization"
- define Cas9 protein
- define nuclease-deficient sgRNA-mediated nuclease
- define functional fragment
- define transcriptional modulator
- define sample
- define subject
- define other terms

### Method for Identification of a Radiotherapy Sensitizer

- adapt CRISPRi technology for lncRNA identification
- describe method for obtaining radiotherapy sensitizers
- detail dCas9 domain fusion with transcriptional activator or repressor
- outline radiation treatment and cell selection process
- identify radiotherapy sensitizer using RNA-seq analysis

### Methods of Diagnosis and Treatment

- diagnose malignant glioma
- detect lncGRSs in sample
- correlate binding to diagnosis
- provide treatment regime
- knockdown lncGRS expression
- administer therapeutically effective amount
- combine with radiation therapy
- define methods of diagnosis and treatment
- describe target lncGRS and agents
- outline methods of inhibiting growth and/or proliferation of glioma cells
- specify embodiments of target lncGRS and agents
- describe administration of agents
- determine effective amounts of agents

### Pharmaceutical Compositions

- define pharmaceutical composition
- describe active ingredients
- discuss carrier and formulation options
- outline methods for preparing administrable compositions

### Three-Dimensional Human Brain Organoid of Malignant Glioma

- introduce three-dimensional human brain organoids
- describe generation of mature brain organoids
- outline method for generating human brain organoid model of malignant glioma
- discuss use of human brain organoid model for screening therapeutics
- describe method for screening agents that synergize with radiation

### Systems

- define lncRNA detection system

## EXAMPLES

### Example 1

- introduce lncRNAs as therapeutic targets in glioma
- describe CRISPRi-based radiation modifier screen
- detail cell culture and radiation treatment methods
- outline CRISPRi screen and hit analysis procedures
- describe RT-qPCR, subcellular fractionation, and FISH methods
- detail Western blot, immunohistochemistry, and flow cytometry methods
- describe antisense oligonucleotide design and transfection methods
- outline RNA-seq sample preparation, data analysis, and mature brain organoid generation methods
- describe cell culture preparation
- outline CRISPRi platform for radiotherapy sensitization
- summarize CRISPRi screen for lncRNA glioma radiation sensitizers
- detail CRISPRi-mediated knockdown of lncGRS-1
- report results of lncGRS-1 knockdown in glioma cells
- validate lncGRS-1 as therapeutic target
- demonstrate CRISPRi-mediated lncGRS-1 knockdown
- show ASO-mediated lncGRS-1 knockdown efficacy
- investigate lncGRS-1 knockdown in non-tumorigenic cells
- analyze RNA-seq data following lncGRS-1 knockdown
- evaluate ASO-mediated lncGRS-1 knockdown in mature brain organoids
- discuss CRISPRi-based pooled screening platform
- conclude on lncGRS-1 as a potential therapeutic target

